Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Gilead Sciences
With
Arcus Biosciences, Inc.
The study includes multiple substudy arms (Substudy A, B, C), which will evaluate immunotherapy-based combinations.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented Stage IV metastatic, NSCLC
Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1
At least one measurable target lesion per RECIST v1.1.
Adequate organ function
Participants must be willing to provide adequate tumor tissue
You may not be if
Underlying medical conditions that, in the Investigator's or Sponsor's opinion, will make the administration of Investigational Product(s) (IPs) hazardous
Use of any live vaccines against infectious diseases within 28 days of first dose of IP(s).
Use of supra-physiologic doses of corticosteroids (\> 10 mg/day of oral prednisone or equivalent) or immunosuppressive medications ≤ 14 days before the initiation of study treatment (absorbable topical corticosteroids are not excluded).
Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
Any active autoimmune disease or a documented history of autoimmune disease or syndrome that required systemic treatment in the past 2 years (ie, with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs), except for vitiligo or resolved childhood asthma/atopy
